Literature DB >> 20862570

Behçet's syndrome.

Yusuf Yazici1, Sebahattin Yurdakul, Hasan Yazici.   

Abstract

Behçet's syndrome is a systemic vasculitis with an unknown etiology affecting the small and large vessels of the venous and arterial systems. At least two clusters of disease expression have been described. The first includes superficial vein thrombosis, deep vein thrombosis, and dural sinus thrombi. The second includes acne, arthritis, and enthesitis. The presence of these clusters suggests there may be more than one disease mechanism operative in this complex disorder. Recent European League Against Rheumatism guidelines are useful for the management of the disease in organ systems distinct from the vascular, neurological, and gastrointestinal systems. This is because of a lack of controlled studies evaluating such vascular, neurological, and gastrointestinal complications.

Entities:  

Mesh:

Year:  2010        PMID: 20862570     DOI: 10.1007/s11926-010-0132-z

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  43 in total

1.  EULAR recommendations for the management of Behçet disease.

Authors:  G Hatemi; A Silman; D Bang; B Bodaghi; A M Chamberlain; A Gul; M H Houman; I Kötter; I Olivieri; C Salvarani; P P Sfikakis; A Siva; M R Stanford; N Stübiger; S Yurdakul; H Yazici
Journal:  Ann Rheum Dis       Date:  2008-01-31       Impact factor: 19.103

Review 2.  Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease.

Authors: 
Journal:  Lancet       Date:  1990-05-05       Impact factor: 79.321

3.  Histopathologic features of the spontaneous pustular lesions of Behçet's syndrome.

Authors:  T Ergun; O Gürbüz; G Dogusoy; C Mat; H Yazici
Journal:  Int J Dermatol       Date:  1998-03       Impact factor: 2.736

4.  Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behçet's disease.

Authors:  K Masuda; A Nakajima; A Urayama; K Nakae; M Kogure; G Inaba
Journal:  Lancet       Date:  1989-05-20       Impact factor: 79.321

5.  Clinical patterns of neurological involvement in Behçet's disease: evaluation of 200 patients. The Neuro-Behçet Study Group.

Authors:  G Akman-Demir; P Serdaroglu; B Tasçi
Journal:  Brain       Date:  1999-11       Impact factor: 13.501

6.  Behçet's disease. Relation of serum C-reactive protein and erythrocyte sedimentation rates to disease activity.

Authors:  A U Müftüoğlu; H Yazici; S Yurdakul; Y Tüzün; H Pazarli; G Güngen; S Deniz
Journal:  Int J Dermatol       Date:  1986-05       Impact factor: 2.736

7.  Familial aggregation of Behçet's disease in Turkey.

Authors:  A Gül; M Inanç; L Ocal; O Aral; M Koniçe
Journal:  Ann Rheum Dis       Date:  2000-08       Impact factor: 19.103

8.  Short-term trial of etanercept in Behçet's disease: a double blind, placebo controlled study.

Authors:  Melike Melikoglu; Izzet Fresko; Cem Mat; Yilmaz Ozyazgan; Feride Gogus; Sebahattin Yurdakul; Vedat Hamuryudan; Hasan Yazici
Journal:  J Rheumatol       Date:  2005-01       Impact factor: 4.666

9.  The frequency of scarring after genital ulcers in Behçet's syndrome: a prospective study.

Authors:  M Cem Mat; Nadir Goksugur; Burhan Engin; Sabahattin Yurdakul; Hasan Yazici
Journal:  Int J Dermatol       Date:  2006-05       Impact factor: 2.736

10.  Interferon alfa-2a in the treatment of Behçet disease: a randomized placebo-controlled and double-blind study.

Authors:  Erkan Alpsoy; Cicek Durusoy; Ertan Yilmaz; Yilmaz Ozgurel; Oya Ermis; Sahin Yazar; Erdal Basaran
Journal:  Arch Dermatol       Date:  2002-04
View more
  34 in total

1.  Identification of Novel Biomarkers for Behcet Disease Diagnosis Using Human Proteome Microarray Approach.

Authors:  Chao-Jun Hu; Jian-Bo Pan; Guang Song; Xiao-Ting Wen; Zi-Yan Wu; Si Chen; Wen-Xiu Mo; Feng-Chun Zhang; Jiang Qian; Heng Zhu; Yong-Zhe Li
Journal:  Mol Cell Proteomics       Date:  2016-10-24       Impact factor: 5.911

Review 2.  Improvement of neurological and ocular symptoms of Behçet's disease after the introduction of infliximab.

Authors:  Marko Barešić; Mirna Reihl; Mario Habek; Nenad Vukojević; Branimir Anić
Journal:  Rheumatol Int       Date:  2018-05-17       Impact factor: 2.631

3.  Association of Rho-kinase 1 (ROCK1) gene polymorphisms with Behçet's disease.

Authors:  Elif Oguz; Abdullah Tuncay Demiryürek; Yavuz Pehlivan; Bünyamin Kisacik; Esma Ozkara; Serdar Oztuzcu; Belgin Alasehirli; Ahmet Mesut Onat
Journal:  Mol Diagn Ther       Date:  2014-08       Impact factor: 4.074

4.  Colchicine modulates oxidative stress in serum and neutrophil of patients with Behçet disease through regulation of Ca²⁺ release and antioxidant system.

Authors:  Selma Korkmaz; Ijlal Erturan; Mustafa Nazıroğlu; Abdulhadi Cihangir Uğuz; Bilal Ciğ; Ishak Suat Övey
Journal:  J Membr Biol       Date:  2011-11-04       Impact factor: 1.843

Review 5.  Gastrointestinal Behçet's disease: a review.

Authors:  Wasseem Skef; Matthew J Hamilton; Thurayya Arayssi
Journal:  World J Gastroenterol       Date:  2015-04-07       Impact factor: 5.742

Review 6.  Familial Mediterranean fever: An updated review.

Authors:  İsmail Sarı; Merih Birlik; Timuçin Kasifoğlu
Journal:  Eur J Rheumatol       Date:  2014-03-01

7.  Clinical significance of Angiopoietin-1 in Behcet's disease patients with vascular involvement.

Authors:  Iman H Bassyouni; Mohammed Sharaf; Iman E Wali; Hossam M Mansour
Journal:  Heart Vessels       Date:  2015-05-12       Impact factor: 2.037

8.  Soluble levels of osteopontin in patients with Behcet's disease: association with disease activity and vascular involvement.

Authors:  Iman H Bassyouni; Mohammed M El-Wakd; Rasha H Bassyouni
Journal:  J Clin Immunol       Date:  2012-10-25       Impact factor: 8.317

Review 9.  Behcet's Syndrome.

Authors:  Sam R Dalvi; Resit Yildirim; Yusuf Yazici
Journal:  Drugs       Date:  2012-12-03       Impact factor: 9.546

10.  Risk of Pulmonary Embolism and Deep Venous Thrombosis in Systemic Sclerosis: A General Population-Based Study.

Authors:  Sara R Schoenfeld; Hyon K Choi; Eric C Sayre; J Antonio Aviña-Zubieta
Journal:  Arthritis Care Res (Hoboken)       Date:  2016-02       Impact factor: 4.794

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.